These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 20604570)

  • 21. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.
    Martínez-Chávez A; Loos NHC; Lebre MC; Tibben MM; Rosing H; Beijnen JH; Schinkel AH
    Pharmacol Res; 2022 Apr; 178():105954. PubMed ID: 34700018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values.
    Tachibana T; Kato M; Sugiyama Y
    Pharm Res; 2012 Mar; 29(3):651-68. PubMed ID: 21913031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis.
    Uno S; Kawase A; Tsuji A; Tanino T; Iwaki M
    Drug Metab Pharmacokinet; 2007 Aug; 22(4):313-21. PubMed ID: 17827786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Hepatic and Intestinal Efflux Transport of Statins.
    Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
    Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
    Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
    Sun X; Tang S; Hou B; Duan Z; Liu Z; Li Y; He S; Wang Q; Chang Q
    BMC Gastroenterol; 2021 Jan; 21(1):2. PubMed ID: 33407159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib.
    Li W; Sparidans RW; Martins MLF; El-Lari M; Lebre MC; van Tellingen O; Beijnen JH; Schinkel AH
    Mol Cancer Ther; 2021 Jun; 20(6):1173-1182. PubMed ID: 33785654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
    Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G; Rostami-Hodjegan A
    Drug Metab Dispos; 2016 Mar; 44(3):476-80. PubMed ID: 26842595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples.
    Canaparo R; Nordmark A; Finnström N; Lundgren S; Seidegård J; Jeppsson B; Edwards RJ; Boobis AR; Rane A
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):240-8. PubMed ID: 17371528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study.
    Maeda K; Takano J; Ikeda Y; Fujita T; Oyama Y; Nozawa K; Kumagai Y; Sugiyama Y
    Clin Pharmacol Ther; 2011 Aug; 90(2):263-70. PubMed ID: 21716273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
    Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
    J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
    Tachibana T; Kato M; Takano J; Sugiyama Y
    Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.
    Wilson A; Tirona RG; Kim RB
    Inflamm Bowel Dis; 2017 May; 23(5):804-813. PubMed ID: 28301431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.
    Benet LZ; Cummins CL; Wu CY
    Int J Pharm; 2004 Jun; 277(1-2):3-9. PubMed ID: 15158963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.